Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
Glucotrack (GCTK) delivers innovative diabetes management solutions through non-invasive and implantable glucose monitoring technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market developments.
Access real-time information about regulatory milestones, product certifications, and strategic partnerships. Our curated feed includes earnings reports, clinical trial outcomes, and technology updates directly impacting GCTK's position in the medical device sector.
Key coverage areas include FDA/EU regulatory progress, implantable CBGM system trials, and commercial expansion initiatives. Bookmark this page for streamlined tracking of Glucotrack's progress in revolutionizing blood glucose measurement through cutting-edge ultrasound and electromagnetic technologies.
GlucoTrack, Inc. (NASDAQ:GCTK) announced a $10 million underwritten public offering led by Aegis Capital Corp. as the sole bookrunner on April 17, 2023. The funds are intended to support the company's mission of developing non-invasive glucose monitoring devices for diabetes patients. Founded in 2001 and based in Or Yehuda, Israel, GlucoTrack is focused on providing an alternative to traditional glucose measurement methods, thereby improving the quality of life for diabetics and pre-diabetics. The company aims to enhance its product offerings and expand its market reach with the new capital raised from this offering.
FAQ
What is the current stock price of Glucotrack (GCTK)?
What is the market cap of Glucotrack (GCTK)?
